- Home
- EXEL vs SIGA Comparison
EXEL vs SIGA Comparison
Compare EXEL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | SIGA |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 341.0M |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EXEL | SIGA |
|---|---|---|
| Price | $50.11 | $4.20 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $46.50 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 427.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $13.13 | $224.81 |
| P/E Ratio | $64.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.76 | $4.25 |
| 52 Week High | $51.63 | $9.62 |
Technical Indicators
Market Signals| Indicator | EXEL | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 32.55 |
| Support Level | $40.17 | N/A |
| Resistance Level | N/A | $4.80 |
| Average True Range (ATR) | 1.60 | 0.17 |
| MACD | 0.51 | -0.01 |
| Stochastic Oscillator | 82.66 | 17.58 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.